Knowledge of biosimilars and perceptions of the naming conventions for biosimilar products in clinical practice in the United States.

ABSTRACT:

Background

Biosimilar therapies and their naming conventions are both relatively new to the drug development market and in clinical practice. We studied the use of the four-letter naming convention in practice and the knowledge, perceptions, and preferences of US health care providers.

Methods

A survey was distributed among health care professionals with a history of utilizing biosimilars in clinical practice to measure key knowledge and the presence of discernable naming trends. Differences in responses across pre-hypothesized subgroups were tested for statistical significance.

Results

Of the 506 surveys emailed, 83 (16%) people responded. Overall, there was poor knowledge about the key concepts surrounding biosimilars. For example, only 52% of respondents correctly

SUBMITTER: Olave M 

PROVIDER: S-EPMC8547319 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature